MEDICAL POLICY – 7.01.148
Endovascular Therapies for Extracranial Vertebral Artery Disease

BCBSA Ref. Policy: 7.01.148
Effective Date: Aug. 1, 2018
Last Revised: July 25, 2018
Replaces: N/A

RELATED MEDICAL POLICIES: None

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | CODING | RELATED INFORMATION
EVIDENCE REVIEW | REFERENCES | HISTORY

Clicking this icon returns you to the hyperlinks menu above.

Introduction

The vertebral arteries travel along the spine, up the back of the neck, and enter the brain. When one of these arteries is narrowed, blocked, or there is a bulge before it enters the brain, it's known as extracranial vertebral artery disease. (Extracranial means outside the skull.) Treatment usually involves medication or surgery. Other techniques that are done inside the blood vessels are being studied. These techniques are known as endovascular therapies. An example of an endovascular therapy is placing a tiny tube inside a blocked artery to allow blood to flow through it. Endovascular therapy for extracranial vertebral artery disease is investigational. These techniques are still being studied to see if they are as effective as standard treatments.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
Endovascular therapy, including percutaneous transluminal angioplasty with or without stenting, is considered investigational for the management of extracranial vertebral artery disease.

**Note:** The extracranial vertebral artery is considered to be segments V1-V3 of the vertebral artery from its origin at the subclavian artery until it crosses the dura mater.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0075T</td>
<td>Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; initial vessel</td>
</tr>
<tr>
<td>0076T</td>
<td>Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; each additional vessel (List separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

N/A
Description

Vertebral artery diseases, including atherosclerotic stenosis, dissections, and aneurysms, can lead to ischemia of the posterior cerebral circulation. Conventional management of extracranial vertebral artery diseases may include medical therapy (e.g., antiplatelet or anticoagulant medications), medications to reduce atherosclerotic disease risk (e.g., statins), and/or surgical revascularization. Endovascular therapies have been investigated as an alternative to conventional management.

Background

Vertebrobasilar Circulation Ischemia

Ischemia of the vertebrobasilar or posterior circulation accounts for about 20% of all strokes. Posterior circulation strokes may arise from occlusion of the innominate and subclavian arteries, the extracranial vertebral arteries, or the intracranial vertebral, basilar, or posterior cerebral arteries. Compared with carotid artery disease, relatively little is known about the true prevalence of specific causes of posterior circulation strokes, particularly the prevalence of vertebral artery disease. A report from a stroke registry, Gulli et al (2013), estimated that in 9% of cases posterior circulation strokes are due to stenosis of the proximal vertebral artery.\(^1\) Patients who experience strokes or transient ischemic attacks of the vertebrobasilar circulation face a 25% to 35% risk of stroke within the subsequent 5 years. In particular, the presence of vertebral artery stenosis increases the 90-day risk of recurrent stroke by about 4-fold.

Relevant Clinical Anatomy and Pathophysiology

Large artery disease of the posterior circulation may be due to atherosclerosis (stenosis), embolism, dissection, or aneurysms. In about a third of cases, posterior circulation strokes are due to stenosis of the extracranial vertebral arteries or the intracranial vertebral, basilar, and posterior cerebral arteries. The proximal portion of the vertebral artery in the neck is the most common location of atherosclerotic stenosis in the posterior circulation. Dissection of the extracranial or intracranial vertebral arteries may also cause posterior circulation ischemia. By contrast, posterior cerebral artery ischemic events are more likely to be secondary to embolism from more proximal vessels.

The vertebral artery is divided into 4 segments, V1-V4, of which segments V1-V3 are extracranial. V1 originates at the subclavian artery and extends to the C5 or C6 vertebrae; V2
crosses the bony canal of the transverse foramina from C2 to C5; V3 starts as the artery exits the transverse foramina at C2 and ends as the vessel crosses the dura matter and becomes an intracranial vessel. The most proximal segment (V1) is the most common location for atherosclerotic occlusive disease to occur, while arterial dissections are most likely to involve the extracranial vertebral artery just before the vessel crosses the dura mater. Compared with the carotid circulation, the vertebral artery system is more likely to be associated with anatomic variants, including a unilateral artery.

Atherosclerotic disease of the vertebral artery is associated with conventional risk factors for cerebrovascular disease. However, risk factors and the underlying pathophysiology of vertebral artery dissection and aneurysms differ. Extracranial vertebral artery aneurysms and dissections are most often secondary to trauma, particularly those with excessive rotation, distraction, or flexion/extension, or iatrogenic injury, such as during cervical spine surgeries. Spontaneous vertebral artery dissections are rare, and in many cases are associated with connective tissue disorders including Ehlers-Danlos syndrome type IV, Marfan syndrome, autosomal-dominant polycystic kidney disease, and osteogenesis imperfecta type I.\textsuperscript{2}

**Management of Extracranial Vertebral Artery Disease**

The optimal management of occlusive extracranial vertebral artery disease is not well defined. Medical treatment with antiplatelet or anticoagulant medications is a mainstay of therapy to reduce stroke risk. Medical therapy also typically involves risk reduction for classical cardiovascular risk factors. However, no randomized trials have compared specific antiplatelet or anticoagulant regimens.

Surgical revascularization may be used for vertebral artery atherosclerotic disease, but open surgical repair is considered technically challenging due to poor access to the vessel origin. Surgical repair may involve vertebral endarterectomy, bypass grafting, or transposition of the vertebral artery, usually to the common or internal carotid artery. Moderately sized single-center case series of surgical vertebral artery repair from 2012 and 2013 have reported overall survival rates of 91\% and 77\% at 3 and 6 years postoperatively, respectively, and arterial patency rates of 80\% after 1 year of follow-up.\textsuperscript{3,4} Surgical revascularization may be used when symptomatic vertebral artery stenosis is not responsive to medical therapy, particularly when bilateral vertebral artery stenosis is present or when unilateral stenosis is present in the presence of an occluded or hypoplastic contralateral vertebral artery. Surgical revascularization may also be considered in patients with concomitant symptomatic carotid and vertebral disease who do not have relief of vertebrobasilar ischemia after carotid revascularization.
The management of extracranial vertebral artery aneurysms or dissections is controversial due to uncertainty about the risk of thromboembolic events associated with aneurysms and dissections. Antiplatelet therapy is typically used; surgical repair, which may include vertebral bypass, external carotid autograft, and vertebral artery transposition to the internal carotid artery, or endovascular treatment with stent placement or coil embolization, may also be used.

Given the technical difficulties related to surgically accessing the extracranial vertebral artery, endovascular therapies have been investigated for extracranial vertebral artery disease. Endovascular therapy may consist of percutaneous transluminal angioplasty, with or without stent implantation.

**Summary of Evidence**

For individuals with extracranial vertebral artery stenosis who receive percutaneous transluminal angioplasty with or without stent implantation, the evidence includes RCTs and noncomparative studies. Relevant outcomes are overall survival, symptoms, morbid events, and treatment-related mortality and morbidity. Two RCTs, the Vertebral Artery Stenting Trial and the Vertebral Artery Stenting Trial, found no advantage for endovascular intervention compared with best medical therapy alone. Evidence from noncomparative studies has shown that vertebral artery stenting can be performed with high rates of technical success and low periprocedural morbidity and mortality, and that vessel patency can be achieved in a high percentage of cases. However, long-term follow-up has demonstrated high rates of in-stent stenosis. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with extracranial vertebral artery aneurysm(s), dissection(s), and arteriovenous fistula(e) who receive percutaneous transluminal angioplasty with stent implantation, the evidence includes small case series and case reports. Relevant outcomes are overall survival, symptoms, morbid events, and treatment-related mortality and morbidity. The available evidence indicates that endovascular therapy for extracranial vertebral artery disorders other than stenosis is feasible and may be associated with favorable outcomes. However, given the lack of data comparing endovascular therapies to alternatives, the evidence is insufficient to permit conclusions about the efficacy of endovascular therapy for extracranial vertebral artery aneurysms, dissections, and arteriovenous fistulae. The evidence is insufficient to determine the effects of the technology on health outcomes.
Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov in April 2018 did not identify any ongoing or unpublished trials that would likely influence this review.

Practice Guidelines and Position Statements

**American Heart Association and American Stroke Association**

In 2014, the American Heart Association and American Stroke Association issued joint guidelines on prevention of stroke in patients with stroke and transient ischemic attack, which made the following recommendations about treatment of extracranial vertebrobasilar disease (see Table 1).

**Table 1. Guidelines on Stroke Prevention in Patients with Stroke and Transient Ischemic Attack**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>COR</th>
<th>LOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Routine preventive therapy with emphasis on anti-thrombotic therapy, lipid lowering, BP control, and lifestyle optimization is recommended for all patients with recently symptomatic extracranial vertebral artery stenosis.”</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>“Endovascular stenting of patients with extracranial vertebral stenosis may be considered when patients are having symptoms despite optimal medical treatment.”</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>“Open surgical procedures, including vertebral endarterectomy and vertebral artery transposition, may be considered when patients are having symptoms despite optimal medical treatment.”</td>
<td>IIb</td>
<td>C</td>
</tr>
</tbody>
</table>

BP: blood pressure; COR: class of recommendation; LOE: level of evidence.

**American Stroke Association et al**

In 2011, a multisociety task force issued guidelines on the management of extracranial vertebral and carotid artery disease, which made the following statements about catheter-based revascularization of extracranial vertebral artery disease: “Although angioplasty and stenting of the vertebral vessels are technically feasible, as for high-risk patients with carotid disease, there is insufficient evidence from randomized trials to demonstrate that endovascular management is
superior to best medical management.”

No specific recommendations were made regarding endovascular therapies.

**Medicare National Coverage**

Centers for Medicare & Medicaid Services has a national coverage determination addressing the use of percutaneous transluminal angioplasty in the treatment of atherosclerotic obstructive lesions of the lower or the upper extremities (not including the head or neck vessels), of a single coronary artery, of renal arteries, and of arteriovenous dialysis fistulas and grafts. It also addresses the use of percutaneous transluminal angioplasty concurrent with carotid stent placement in Food and Drug Administration investigational device exemption clinical trials, in FDA-approved postapproval studies, and in patients at high risk for carotid endarterectomy.

The national coverage determination states that all other indications for percutaneous transluminal angioplasty, with or without stenting, to treat obstructive lesions of the vertebral and cerebral arteries remain non-covered.

**Regulatory Status**

Currently, no endovascular therapies have been approved by the U.S. Food and Drug Administration (FDA) specifically for treatment of extracranial vertebral artery disease.

Various stents, approved for use in the carotid or coronary circulation, have been used for extracranial vertebral artery disease. These stents may be self- or balloon-expandable.

Two devices have been approved by FDA through the humanitarian device exemption process for intracranial atherosclerotic disease. This form of FDA approval is available for devices used to treat conditions with an incidence of 4000 or less per year; FDA only requires data showing “probable safety and effectiveness.” Devices with their labeled indications are as follows:

1. **Neurolink System®** (Guidant). “The Neurolink system is indicated for the treatment of patients with recurrent intracranial stroke attributable to atherosclerotic disease refractory to medical therapy in intracranial vessels ranging from 2.5 to 4.5 mm in diameter with ≥50% stenosis and that are accessible to the stent system.”

to medical therapy, in intracranial vessels with ≥50% stenosis that are accessible to the system.”

References


### History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/14/15</td>
<td>New Policy. Policy created with literature review through January 6, 2015. Endovascular therapy for extracranial vertebral artery disease considered investigational.</td>
</tr>
<tr>
<td>05/27/15</td>
<td>Minor update. Notation added to Policy Guidelines section: CPT codes 0075T and 0076T should only be utilized if the procedure is related to vertebral arteries.</td>
</tr>
</tbody>
</table>
**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2018 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
CIVIL RIGHTS COORDINATOR - COMPLAINTS AND APPEALS
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5592, TTY 800-842-5357
Email AppealsDepartment@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
U.S. Department of Health and Human Services
200 Independence Avenue SW, Room 509F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-5797 (TDD)

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-842-5357).

阿拉伯 (Arabic):
يجب أن تكون هذه المعلومات متوفرة للجميع، بما في ذلك الأشخاص ذوي الإعاقة. لا تلغى مزاياك في حالة التمييز.

Oromoo (Cushite):
Oromoo Blue Cross: 800-722-1471 (TTY: 800-842-5357) 

中文 (Chinese):
本通知有重要的訊息。本通知可能有關於您透過 Premera Blue Cross 提交的申請或保障的重要な訊息。本通知可能有重要日期。您可能需要在截止日期之前採取行動。以保留您的健康保險或費用補貼。您有權利免費以您的母語得到本訊息和幫助。請撥電話 800-722-1471 (TTY: 800-842-5357)。
Premera Blue Cross is committed to providing high-quality healthcare services. We are here to help you understand your rights and responsibilities under your health insurance plan.

To learn more about your benefits, contact Premera Blue Cross through our TTY line at 800-722-1471.

If you need additional assistance, please call us at 800-842-5357.

Română (Romanian):

Russian (Russian):
Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется принять меры к определенным предъядачным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357).

Español (Spanish):
Este Aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud o cobertura a través de Premera Blue Cross. Es posible que haya fechas clave en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357).

Tagalog (Tagalog):
Ang Pagawa na ito ay naglalaman ng mahalagang impormasyon. Ang pagawa na ito ay naglalaman ng mahalagang impormasyon tungkol sa iyong aplikasyon o pagsakop sa pamagatang ng Premera Blue Cross. Magalarin may mga mahalagang petsa dito sa paunawa. Maaring mangailangan ka na nagasaan ng kabag sa ilang mga itakad anhinga unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unahan unana...